V

Vir Biotechnology
D

VIR

9.58000
USD
-0.22
(-2.24%)
مغلق
حجم التداول
17,209
الربح لكل سهم
-3
العائد الربحي
-
P/E
-2
حجم السوق
1,319,358,750
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    AAL
    -0.635
    (-4.00%)
    15.225 USD
    BA
    BA
    -3.550
    (-1.96%)
    177.320 USD
    BNTX
    BNTX
    2.240
    (1.90%)
    120.100 USD
    CCL
    CCL
    -1.335
    (-5.44%)
    23.220 USD
    DAL
    DAL
    -3.770
    (-5.91%)
    59.980 USD
    GSK
    GSK
    -0.320
    (-0.87%)
    36.650 USD
    MRNA
    MRNA
    1.785
    (5.29%)
    35.535 USD
    N
    NCLH
    -1.555
    (-6.05%)
    24.130 USD
    N
    NVAX
    0.05500
    (0.69%)
    7.98000 USD
    S
    SPCE
    -0.18000
    (-4.06%)
    4.25000 USD
    U
    UAL
    -6.540
    (-6.38%)
    95.930 USD
    المزيد
الأخبار
المقالات

العنوان: Vir Biotechnology

القطاع: Healthcare
الصناعة: Biotechnology
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development,collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.